124 related articles for article (PubMed ID: 29722125)
21. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
22. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
Jung SH
Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
[TBL] [Abstract][Full Text] [Related]
23. Optimal three-stage designs for phase II cancer clinical trials.
Chen TT
Stat Med; 1997 Dec; 16(23):2701-11. PubMed ID: 9421870
[TBL] [Abstract][Full Text] [Related]
24. A two-stage phase II clinical trial design with nested criteria for early stopping and efficacy.
DeVeaux M; Kane M; Wei W; Zelterman D
Pharm Stat; 2019 Nov; 18(6):700-713. PubMed ID: 31507079
[TBL] [Abstract][Full Text] [Related]
25. An adaptive two-stage design with treatment selection using the conditional error function approach.
Wang J
Biom J; 2006 Aug; 48(4):679-89. PubMed ID: 16972720
[TBL] [Abstract][Full Text] [Related]
26. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
Shan G; Ma C; Hutson AD; Wilding GE
J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
[TBL] [Abstract][Full Text] [Related]
27. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
28. Optimal adaptive two-stage designs for phase II cancer clinical trials.
Englert S; Kieser M
Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
[TBL] [Abstract][Full Text] [Related]
29. Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions.
Chen C; Beckman RA
J Biopharm Stat; 2009; 19(3):424-36. PubMed ID: 19384686
[TBL] [Abstract][Full Text] [Related]
30. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
Zhang Y; Mietlowski W; Chen B; Wang Y
J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
[TBL] [Abstract][Full Text] [Related]
31. Single-arm phase IIA clinical trials with go/no-go decisions.
Zhong B
Contemp Clin Trials; 2012 Nov; 33(6):1272-9. PubMed ID: 22796490
[TBL] [Abstract][Full Text] [Related]
32. A two-stage phase II trial design utilizing both primary and secondary endpoints.
Lin X; Allred R; Andrews G
Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
[TBL] [Abstract][Full Text] [Related]
33. Practical characteristics of adaptive design in phase 2 and 3 clinical trials.
Sato A; Shimura M; Gosho M
J Clin Pharm Ther; 2018 Apr; 43(2):170-180. PubMed ID: 28850685
[TBL] [Abstract][Full Text] [Related]
34. Optimal two-stage log-rank test for randomized phase II clinical trials.
Kwak M; Jung SH
J Biopharm Stat; 2017; 27(4):639-658. PubMed ID: 27050043
[TBL] [Abstract][Full Text] [Related]
35. Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring.
Ray HE; Rai SN
Pharm Stat; 2012; 11(2):170-6. PubMed ID: 22232063
[TBL] [Abstract][Full Text] [Related]
36. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.
Jiang W; Mahnken JD; He J; Mayo MS
Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063
[TBL] [Abstract][Full Text] [Related]
37. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.
Wason JM; Mander AP; Eisen TG
Eur J Cancer; 2011 May; 47(7):983-9. PubMed ID: 21239164
[TBL] [Abstract][Full Text] [Related]
38. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
Kunz CU; Kieser M
Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
[TBL] [Abstract][Full Text] [Related]
39. Sample size adjustment designs with time-to-event outcomes: A caution.
Freidlin B; Korn EL
Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
[TBL] [Abstract][Full Text] [Related]
40. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
